| Therapeutic Area | Indication | Clinical phase | Clinical trial name | Code |
|---|---|---|---|---|
| Dermatology | Hidradenitis Suppurativa (HS) | PHASE 3 | VELA-1 | NCT06411899 |
| Hidradenitis Suppurativa (HS) | PHASE 3 | VELA-2 | NCT06411379 | |
| Adolescent Hidradenitis Suppurativa (Teen HS) | PHASE 3 | VELA-TEEN | - | |
| Palmoplantar Pustulosis (PPP) | PHASE 2 | LEDA | 2024-513305-32-00 | |
| Psoriasis (PsO) | PHASE 3 READY |
| Rheumatology | Psoriatic Arthritis (PsA) | PHASE 3 | IZAR-1 | NCT06641076 |
| Psoriatic Arthritis (PsA) | PHASE 3 | IZAR-2 | NCT06641089 | |
| Axial spondyloarthritis (axSpA) | PHASE 2 | S-OLARIS | 2024-513498-36-00 | |
| PsA (+ axSpA) | PHASE 2 | P-OLARIS | 2024-514504-13-00 |
MoonLake sponsors innovative research and clinical trials globally, targeting inflammatory diseases with major unmet medical need where Sonelokimab has the potential to transform patient outcomes.
